0001493152-21-009302.txt : 20210420
0001493152-21-009302.hdr.sgml : 20210420
20210420214421
ACCESSION NUMBER: 0001493152-21-009302
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210416
FILED AS OF DATE: 20210420
DATE AS OF CHANGE: 20210420
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rivard Paul
CENTRAL INDEX KEY: 0001857479
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36268
FILM NUMBER: 21839326
MAIL ADDRESS:
STREET 1: C/O AKERS BIOSCIENCES, INC.
STREET 2: 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MyMD Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001321834
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 000000000
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1185 AVENUE OF THE AMERICAS
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 856-848-8698
MAIL ADDRESS:
STREET 1: 1185 AVENUE OF THE AMERICAS
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Akers Biosciences, Inc.
DATE OF NAME CHANGE: 20170413
FORMER COMPANY:
FORMER CONFORMED NAME: Akers Biosciences Inc
DATE OF NAME CHANGE: 20050325
4
1
ownership.xml
X0306
4
2021-04-16
0
0001321834
MyMD Pharmaceuticals, Inc.
MYMD
0001857479
Rivard Paul
1185 AVENUE OF THE AMERICAS, 3RD FLOOR
NEW YORK,
NY
10036
0
1
0
0
EVP of Operations, GC
Stock Option (Right to Buy)
2.5913
2021-04-16
4
A
0
77180
A
2023-04-16
Common Stock
77180
77180
D
Stock Option (Right to Buy)
2.5913
2021-04-16
4
A
0
77180
A
2023-04-16
Common Stock
77180
77180
I
See footnote
Received in exchange for a stock option to acquire 200,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") at $1.00 per share in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share.
These options are fully vested and exercisable.
Received in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share in connection with the Merger.
These shares are jointly held by the reporting person and Jennifer Rivard as trustees for the Paul Rivard and Jennifer Rivard Revocable Living Trust.
/s/ Paul Rivard
2021-04-20